Biperiden hydrochloride

Research use only, not for human use.

Biperiden Hcl (NSC 170950, NSC 84989) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker.

Biperiden Hcl (NSC 170950, NSC 84989) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker.Parkinson Disease Approved.

Biperiden hydrochloride (29.6 μg/ml, 72 hours) can significantly induce apoptosis and inhibit proliferation at high doses in human pancreatic ductal adenocarcinoma cells. Cell Proliferation Assay Cell Line:Panc-1, Panc-2 and BxPC3 human pancreatic ductal adenocarcinoma cells Concentration:29.6 μg/mL Incubation Time:72 hours Result:Inhibited cell proliferation at 72 hours significantly by reducing nuclear c-Rel translocation.

Biperiden hydrochloride (intraperitoneal injection, 10 mg/kg, everyday, 3 weeks) reduces tumor size by 83% in subcutaneous xenograft mouse using Panc-1 human pancreatic ductal adenocarcinoma cells. Biperiden hydrochloride (intraperitoneal injection, 8 mg/kg, every 8 hours, 10 days) can reduce frequency of spontaneous seizures and extracellular hippocampal glutamate levels while cause a long-term decrease in hippocampal excitability. Animal Model:Subcutaneous xenograft mouse using Panc-1 human pancreatic ductal adenocarcinoma cells Dosage:10 mg/kg Administration:Intraperitoneal injection; everyday; 3 weeks Result:Tumor size reduced by 83%.Animal Model:Male Wistar rats (200-250 g) Dosage:8 mg/kg Administration: Intraperitoneal injection; every 8 hours; 10 days Result:Reduced late seizures by about three times with no affecting emotional memory damage.

NSC 170950 | NSC 84989

GPCR/G Protein

mAChR

mAChR

Neurological Disease

Parkinson Disease

1235-82-1

347.922

C21H30ClNO

>98% (HPLC)

10 mM in DMSO

C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O.Cl

1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years